%0 Journal Article
%T Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study.
%A Pérez de José A
%A Carbayo J
%A Pocurull A
%A Bada-Bosch T
%A Cases Corona CM
%A Shabaka A
%A Ramos Terrada N
%A Martinez Valenzuela L
%A Huerta A
%A Fernandez Lorente L
%A Malek-Marín TG
%A Goicoechea M
%J Clin Kidney J
%V 14
%N 2
%D Feb 2021
%M 33623683
%F 5.86
%R 10.1093/ckj/sfz178
%X <B>UNASSIGNED: </B>Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated mixed cryoglobulinaemia (HCV-MC) has been little studied. The aim of this study was to analyse the effects of antiviral treatment on kidney prognosis and evolution in patients diagnosed with HCV-MC.<BR><B>UNASSIGNED: </B>The RENALCRYOGLOBULINEMIC study is an observational multicentre cohort study of 139 patients with HCV-MC from 14 Spanish centres. Clinical and laboratory parameters were measured before and after antiviral treatment. Primary endpoints were kidney survival and mortality after HCV-MC diagnosis. Secondary endpoints were clinical, immunological and virological responses after antiviral treatment.<BR><B>UNASSIGNED: </B>Patients were divided into three groups based on the treatment received: treatment with DAAs (n = 100) treatment with interferon (IFN) and ribavirin (RBV) (n = 24) and no treatment (n = 15). Patients were followed up for a median duration of 138 months (interquartile range 70-251. DAA treatment reduced overall mortality {hazard ratio [HR] 0.12 [95% confidence interval (CI) 0.04-0.40]; P < 0.001} and improved kidney survival [HR 0.10 ( 95% CI 0.04-0.33); P < 0.001].<BR><B>UNASSIGNED: </B>Results from the RENALCRYOGLOBULINEMIC study indicated that DAA treatment in patients with HCV-MC improves kidney survival and reduces mortality.